Advertisement

Topics

PubMed Journals Articles About "Zydus Spies Opportunities Brazil Mexico Along With Biosimilars" RSS

01:52 EST 10th December 2016 | BioPortfolio

Zydus Spies Opportunities Brazil Mexico Along With Biosimilars PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Zydus Spies Opportunities Brazil Mexico Along With Biosimilars articles that have been published worldwide.

More Information about "Zydus Spies Opportunities Brazil Mexico Along With Biosimilars" on BioPortfolio

We have published hundreds of Zydus Spies Opportunities Brazil Mexico Along With Biosimilars news stories on BioPortfolio along with dozens of Zydus Spies Opportunities Brazil Mexico Along With Biosimilars Clinical Trials and PubMed Articles about Zydus Spies Opportunities Brazil Mexico Along With Biosimilars for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Zydus Spies Opportunities Brazil Mexico Along With Biosimilars Companies in our database. You can also find out about relevant Zydus Spies Opportunities Brazil Mexico Along With Biosimilars Drugs and Medications on this site too.

Showing "Zydus spies opportunities Brazil Mexico along with biosimilars" PubMed Articles 1–25 of 2,800+

Attributes of patient-centered primary care associated with the public perception of good healthcare quality in Brazil, Colombia, Mexico and El Salvador.

This study evaluated primary care attributes of patient-centered care associated with the public perception of good quality in Brazil, Colombia, Mexico and El Salvador. We conducted a secondary data analysis of a Latin American survey on public perceptions and experiences with healthcare systems. The primary care attributes examined were access, coordination, provider-patient communication, provision of health-related information and emotional support. A double-weighted multiple Poisson regression with robu...


Biosimilars in oncology: a therapeutic alternative to the reference products?

Biosimilar medicinal products (biosimilars) have been available in Europe for 10 years, allowing a wide use particularly in oncology. Biosimilars are being developed and approved by means of scientifically sound principles to assure close similarity with the reference products with regard to quality, efficacy, and safety. The scientific principles for establishing biosimilarity are the same as those for demonstrating comparability after a change in the manufacturing process of an already licensed biological...

Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia and Mexico.

To estimate economic impact resulting from increased biologics use for treatment of rheumatoid arthritis (RA) and Crohn's disease (CD) in Argentina, Brazil, Colombia, and Mexico.


Three new species of Calliceratomyia Lane (Diptera: Ditomyiidae) from Neotropical Mexico.

Three new species of the ditomyiid genus Calliceratomyia Lane, so far known only from the type-species from southeastern Brazil, are described from Mexico. The new species-Calliceratomyia papaveroi sp. n., Calliceratomyia pantelhomyia sp. n. and Calliceratomyia zayolli sp. n.-are described based on adult males collected with Malaise traps in the States of Oaxaca, Chiapas and Hidalgo, Mexico. The descriptions are illustrated and the diagnosis of the genus is revised.

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.

The Biosimilars Forum conducted a survey through an independent organization from November 20, 2015 to January 4, 2016 in order to assess current levels of awareness, knowledge, and perceptions of biosimilars among US specialty physicians who already prescribe biologics. The survey was intended to provide a baseline level of knowledge about biosimilars and will be repeated in 2-3 years in order to monitor trends over time.

Two new species of the genus Centromacronema Ulmer 1905 (Hydropsychidae: Macronematinae) from Brazil.

Centromacronema is an endemic genus from the Neotropics, with distribution ranging from Mexico to southern Brazil. The genus comprises 15 described species, but only two of them have been recorded in Brazil: Centromacronema               auripenne (Rambur 1842) and C. obscurum (Ulmer 1905). Two new species are herein described and illustrated from   Brazil, C. pioneira n. sp. from Serra da Jiboia, Bahia state, including the first description of a female for the genus, and C. poyanawa n. sp. ...

Biosimilars in Gastroenterology - how much uncertainly is ethically acceptable?

Biosimilars use raises uncertainties with regards to efficacy despite potentially significant cost reductions. This requires a classical harm-benefit analysis. Important stakeholders include physicians and patients, companies producing biologica (drugs containing biotechnology-derived proteins as active substance), and companies producing biosimilars, as well as health insurance companies and politicians. They all have their distinct interests. In a rule-setting process, transparency is needed to protect th...

Opportunities and challenges of extrapolation for biosimilars.

Although biosimilars approved in the European Union have proved to be safe and efficacious, their licensing requirements continue to be disputed by medical professionals. In particular, extrapolation to indications of the originator without one's own clinical data of the biosimilar is controversial. Conceptually, the development of biosimilars is derived from that of generics. However, due to their complexity and inherent variability, considerably more data are necessary for biosimilars to demonstrate compa...

Biosimilars: potential implications for clinicians.

With the expiration of patent protection for several biologics looming, the production of highly similar therapeutic agents has begun to emerge on the pharmaceutical market. These alternative drugs are referred to as biosimilars. Many anticipate that the introduction of these agents will result in a reduction in health care costs, which may create a more affordable biopharmaceutical market and also improve patient access. In contrast to generics, which are exact copies of their original products, biosimilar...

Biosimilars for Psoriasis: Clinical Studies to Determine Similarity.

Biosimilars are drugs that are similar, but not identical, to originator biologics. Pre-clinical analytical studies are required to show similarity on a molecular and structural level, but efficacy and safety studies in humans are essential to ultimately determine biosimilarity. In this review written by members of the International Psoriasis Council, we discuss how biosimilars are evaluated in a clinical setting, with emphasis on extrapolation of indication, interchangeability, and optimal clinical trial d...

The economic implications of biosimilars.

Between 2013 and 2014, spending on specialty drugs, including biologics, increased 32.4%, while spending on small-molecule drugs increased just 6.8%. By 2016, 8 of the 10 top-selling drugs are expected to be biologics. While many biologics will be going off patent, there will likely be multiple prospective manufacturers of biosimilars, and a growing emphasis on regulatory guidelines to ensure their efficacy and safety, in the very near future. A strong factor and assumption surrounding biosimilar developmen...

First Record of Psorophora albipes in Quintana Roo, Mexico.

In Mexico the Psorophora genus includes 24 species divided into 3 subgenera: Grabhamia, Janthinosoma, and Psorophora. Some species occur in the Nearctic region of the country (northern Mexico), whereas other species occur in the Neotropical region (southern Mexico), and a few species occur in both regions. In Quintana Roo, Mexico, 7 species have been previously recorded: Ps. confinnis s.s., Ps. champerico, Ps. cyanescens, Ps. ferox, Ps. lutzii, Ps. ciliata, and Ps. lineata. In October 2013, 24 females of Ps...

Clinical trials for authorised biosimilars in the European Union: A systematic review.

In 2006, Omnitrope (by Sandoz) was the first approved biosimilar in Europe. To date, 21 biosimilars for seven different biologics are on the market. In this paper, the clinical trials undertaken to get market authorisation are compared.

Ambaeolothrips: a new genus of Neotropical Aeolothripidae (Thysanoptera), with observations on the type-species from mango trees in Mexico.

Ambaeolothrips gen. n. is diagnosed for three Neotropical species: the type species romanruizi Ruiz-De la Cruz et al. comb. n. from Mexico, microstriatus Hood comb. n. from Panama, and pampeanus sp. n. from southern Brazil. Variation is discussed among character states that are used in the generic classification of the family Aeolothripidae, including segmentation of the antennae and maxillary palps, sculpture of the metanotum and presence of sternal discal setae. New field observations on the biology of ro...

Biosimilar medicines - Review.

By definition, biosimilars are similar to a biological reference that has already received marketing authorization for biologic drugs.The purpose of biosimilars is reducing costs, thus increasing access to this treatment, however, the concerns of health professionals and users refer to the fact that to reduce costs will not neglecting the quality, effectiveness and especially security.

Biosimilar Medicines Group - 14th Annual Medicines for Europe Conference (April 28-29, 2016 - London, UK).

Biotechnology has enabled the development of treatments for many diseases benefiting millions of people. Similar biologics or 'biosimilar' versions of originator biologic medicines are a relatively new category of biologics, usually developed when the originator is protected by patent exclusivity and introduced to healthcare systems as a cheaper option to treat disease. Biosimilars provide value and thus access for new groups of patients because they bring cost savings to the healthcare ecosystem. Generics ...

Biosimilar medical products - licensing, pharmacovigilance and interchangeability.

The use of biological medicine has significantly increased in recent decades and has made substantial contributions to improving the effectiveness of therapies in many diseases. The expiration of patents of biological innovative medicines enables copies of those drugs called similar biological products (biosimilars) to be approved by regulatory authorities and to enter in clinical use. Biosimilars are comparable but not identical and are not a generic version of the innovator biological product. Although bi...

ENDEMIC ORTHOPOXVIRUS CIRCULATING IN PROCYONIDS IN MEXICO.

Limited serosurveillance studies suggested that orthopoxviruses (OPXV) are widespread in the US (e.g., Raccoonpox virus, Skunkpox virus, Volepox virus) and Brazil (Vaccinia virus); however, their animal reservoir(s) remain unconfirmed. Mexican mammal diversity includes several species related to those in which evidence for OPXV infections has been found (Oryzomys, Peromyscus, Microtus, and Procyonidae). The presence of these groups of mammals in Mexico and the evidence of their possible involvement in the m...

New species and records of Oukuriella Epler, 1986 from the Neotropical region (Diptera: Chironomidae).

Two new species of Oukuriella, O. angelomachadoi sp. nov. (Holotype male deposited in MZUSP: BRAZIL, Paraná State) and O. plumaterata sp. nov. (Holotype male deposited in MZUSP: BRAZIL, São Paulo State), and the immatures stages of O. sublettei are described and figured. The larvae of O. sublettei were collected from submerged woods in low-order streams in the Atlantic Forest. In addition new records of several described species, including the first records of Oukuriella from Mexico and Bolivia are given.

HIV & Hepatitis in the Americas 28-30 April 2016, Mexico City, Mexico.

Practical aspects in the use of biosimilar insulins.

Following the market authorization of the first insulin biosimilar in 2014, further approvals are to be expected due to patent expiry of several originator insulins. Knowledge of the manufacturing and the characteristics of these pharmaceutical products is important for their rationale and safe use by the physician, the pharmacist and the patient.Biosimilars are not generics, but similar or comparable, yet not identical versions of the originator biopharmaceutical. Marketing authorization in the EU is grant...

Using the Portuguese version of the Bicultural Scale in Brazil.

Brazil has received influxes of people, mainly from Africa, Europe and Japan, forming one of the most heterogeneous populations in the world. Some groups, particularly in Southern Brazil, have retained their original cultural traditions, whilst acquiring elements of the typical local Brazilian cultural identity. This is the first study designed to formally evaluate biculturality in Brazil.

Clinical data and regulatory issues of biosimilar products.

Biologics are a fast-growing segment of pharmaceutical development. Many are effective in the treatment of illnesses such as cancers, rheumatoid arthritis, and multiple sclerosis. Biologics encompass a range of compounds, including recombinant hormones, growth factors, monoclonal antibodies, recombinant vaccines, and blood products. Many of these drugs are facing patent expiration, and pharmaceutical research is focusing on the development of generic substitutes, or "biosimilars." Because biologics generall...

Biosimilars and the efficiency principle.

Biosimilars are subject to the efficiency evaluation according to section 106 Social Code Book Five (SGB V). The specific evaluation method influences the physician's prescription behaviour. In the case of an individual prescription limit evaluation (Richtgrößenprüfung), the prescription of biosimilars would usually not result in recourse but, as a start, in the initiation of the evaluation proceedings. Starting from 2017, the individual prescription limit evaluation will be cancelled. The active ingredi...

Lagochilascaris minor (Nematoda: Ascarididae) from a Wild Cougar ( Puma concolor ) in Mexico.

 We document parasitation of a wild cougar ( Puma concolor ) by the nematode Lagochilascaris minor in Hidalgo State, Mexico. This finding contributes to our understanding of the epidemiology of this zoonotic agent in Mexico.


Quick Search
Advertisement